AnatomyOrganismsChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation Science
Cyclin-Dependent Kinase Inhibitor p27Cyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent KinasesCyclinsCell Cycle ProteinsCyclin-Dependent Kinase Inhibitor p16Cell CycleTumor Suppressor ProteinsMicrotubule-Associated ProteinsCyclin-Dependent Kinase 2Cyclin D1Cyclin ACyclin ECell ProliferationCyclin-Dependent Kinase 4CDC2-CDC28 KinasesApoptosisCyclin-Dependent Kinase Inhibitor p57Cell Line, TumorProtein Kinase InhibitorsProtein-Serine-Threonine KinasesG1 PhaseCyclin-Dependent Kinase 5Cyclin BCyclin DCDC2 Protein KinaseCyclin-Dependent Kinase Inhibitor ProteinsCyclin CPhosphorylationCyclin D3Retinoblastoma ProteinCyclin-Dependent Kinase 6Cell DivisionEnzyme InhibitorsS PhaseCyclin B1Cyclin-Dependent Kinase Inhibitor p18Tumor Suppressor Protein p53Proto-Oncogene ProteinsTumor Cells, CulturedSignal TransductionCyclin D2Cells, CulturedPhosphatidylinositol 3-KinasesBlotting, WesternE2F1 Transcription FactorCyclin A1Protein KinasesPurinesTransfectionCell LineMitosisCyclin GG2 PhaseTranscription Factor DP1MutationProliferating Cell Nuclear AntigenCyclin-Dependent Kinase Inhibitor p15DNA-Binding ProteinsCyclin G1MAP Kinase Signaling SystemCyclin A2E2F Transcription FactorsRNA, MessengerMolecular Sequence DataCarrier ProteinsNuclear ProteinsAntineoplastic AgentsTranscription FactorsBase SequenceProtein-Tyrosine KinasesCalcium-Calmodulin-Dependent Protein KinasesImmunohistochemistryCyclin-Dependent Kinase Inhibitor p19S-Phase Kinase-Associated Proteinssrc-Family KinasesEnzyme ActivationDown-RegulationGene Expression RegulationProtein BindingProtein Kinase CReverse Transcriptase Polymerase Chain ReactionDNA DamageTranscription, GeneticIntracellular Signaling Peptides and ProteinsAmino Acid Sequencep38 Mitogen-Activated Protein Kinases3T3 CellsMitogen-Activated Protein KinasesMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase KinasesPromoter Regions, GeneticRNA, Small InterferingPyrimidinesMice, KnockoutTime FactorsCyclic AMP-Dependent Protein KinasesGene Expression Regulation, NeoplasticCell NucleusMitogen-Activated Protein Kinase 3

Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer. (73/73)

We looked for p16/p19 deletion and p16 promoter methylation, as well as loss of 9p21 heterozygosity in pure squamous cell carcinomas (SCC), and in transitional cell carcinomas (TCC) of the bladder with SCC components. Homozygous deletion of p16/p19 was detected in 11 of 21 (52%) cases of pure SCCs and in three of ten (30%) cases of TCC with SCC. Three cases of TCC with SCC had p16/p19 deletion, hypermethylation of the p16 promoter, or LOH on 9p21 only in the SCC components, suggesting that these molecular alterations occurred preferentially in SCC. Interestingly, homozygous deletion of p16/p19 was observed in squamous metaplasia from bladder cancer patients (five of 11, 45%), showing that this change occurred in preneoplastic cells. On the other hand, p16/p19 deletions were not found in squamous metaplasias from non cancerous patients. Hypermethylation of the p16 promoter was observed in two of 14 tumors (14%) and none of seven metaplasias examined. These data suggest that: (a) p16/p19 deletion is associated with early carcinogenesis of SCC of the bladder, and squamous metaplasia of the bladder cancer patient has already sustained genetic changes found in cancer, and (b) genetic mosaicism occurs in cases of TCC with SCC, with the SCC component showing more frequent 9p21 alterations than the TCC component.  (+info)